Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQHU4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,235
Award facts
- Contract value 100% obligated
- $9,234.68 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $9,234.68 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 68 mg Nexplanon implants. The delivery order, issued on December 22, 2025, with an ultimate completion date of January 14, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that positions the company as a regional prime vendor for comprehensive pharmaceutical and medical supply distribution to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial contracting capability within the federal pharmaceutical supply chain since its establishment in 2001, with an extensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's performance on the PPV-G GEN V contract, which carries a ceiling value of $499,999,999 through December 31, 2036, and includes a 30-month base period with three 30-month option periods, positions it as a critical supplier for recurring medical supply needs across the military healthcare system. This delivery order for Nexplanon contraceptive implants exemplifies the specialized pharmaceutical requirements the contractor fulfills to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQHU4?
SPE2DR26FQHU4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 22, 2025.
How much is contract SPE2DR26FQHU4 worth?
The government has obligated $9,235 on SPE2DR26FQHU4.
Is contract SPE2DR26FQHU4 an order under another contract?
Yes. SPE2DR26FQHU4 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHU4 competed?
The extent of competition for SPE2DR26FQHU4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award